Stem Cells International

Stem Cells International / 2016 / Article

Research Article | Open Access

Volume 2016 |Article ID 8470263 | 8 pages | https://doi.org/10.1155/2016/8470263

iPSC-Derived Retinal Pigment Epithelium Allografts Do Not Elicit Detrimental Effects in Rats: A Follow-Up Study

Academic Editor: William L. Stanford
Received14 Jul 2015
Accepted20 Oct 2015
Published05 Jan 2016

Abstract

Phototransduction is accomplished in the retina by photoreceptor neurons and retinal pigment epithelium (RPE) cells. Photoreceptors rely heavily on the RPE, and death or dysfunction of RPE is characteristic of age-related macular degeneration (AMD), a very common neurodegenerative disease for which no cure exists. RPE replacement is a promising therapeutic intervention for AMD, and large numbers of RPE cells can be generated from pluripotent stem cells. However, questions persist regarding iPSC-derived RPE (iPS-RPE) viability, immunogenicity, and tumorigenesis potential. We showed previously that iPS-RPE prevent photoreceptor atrophy in dystrophic rats up until 24 weeks after implantation. In this follow-up study, we longitudinally monitored the same implanted iPS-RPE, in the same animals. We observed no gross abnormalities in the eyes, livers, spleens, brains, and blood in aging rats with iPSC-RPE grafts. iPS-RPE cells that integrated into the subretinal space outlived the photoreceptors and survived for as long as 2 1/2 years while nonintegrating RPE cells were ingested by host macrophages. Both populations could be distinguished using immunohistochemistry and electron microscopy. iPSC-RPE could be isolated from the grafts and maintained in culture; these cells also phagocytosed isolated photoreceptor outer segments. We conclude that iPS-RPE grafts remain viable and do not induce any obvious associated pathological changes.

1. Introduction

The diverse functions of retinal pigment epithelium (RPE) cells are essential for photoreceptor activity [1]. RPE death or dysfunction results in photoreceptor degeneration characteristic of age-related macular degeneration (AMD), the leading cause of vision loss in the elderly [2]. While no cure exists, multiple studies performed in animal models of retinal degeneration and human subjects have provided encouraging evidence that RPE cell replacement prevents photoreceptor atrophy [314]. Multiple independent labs have shown that large numbers of RPE cells can readily be derived from stem cells (SC-RPE—for review see [15]). The use of autologous induced pluripotent stem cells (iPSCs) rather than embryonic stem cells (ESCs) may be advantageous since the risk of graft rejection may be reduced or obviated [1618].

Other groups and ours have characterized SC-RPE using multiple methods. These studies have shown that SC-RPE strongly resemble primary RPE based on morphological, functional, transcriptomic, proteomic, and metabolomic analyses, and, most importantly, they function in vivo to significantly slow retinal degeneration [4, 68, 11, 14, 1924]. With respect to their clinical application, however, there are unresolved concerns including safety and long-term viability of the hES- and iPS-RPE grafts [4, 6, 8, 10, 25]. Evidence from preclinical and early phase clinical trials has shown no adverse ocular effects in rodents or patients with hiPS-RPE or hESC-RPE allografts [9, 10, 13, 2628], but histopathological exams of extraocular tissues have not been completely cataloged. If RPE grafts were short-lived or if they lost functionality over time, multiple subretinal injections, which involve transient macula-off retinal detachment and other risks, would be required for treating the slow and progressive degeneration characteristic of AMD. In carefully controlled experiments involving Cynomolgus Macaque and in human subjects, full visual recovery after macula-off detachments does not occur for roughly 3 months and in 6 months to 1 year after reattachment, respectively [29, 30].

In this study we continued monitoring the same iPS-RPE engrafted animals from our previous report [8] to catalog any gross detrimental ocular and/or systemic effects. In addition, we examined the viability and phagocytic function of the iPS-RPE in aging Royal College of Surgeons (RCS) rats.

2. Methods and Materials

2.1. Animal Studies

A mutation in the MerTK gene renders RPE cells incapable of phagocytosis and induces retinal degeneration in RCS albino rats [31]. Albino strains were used to facilitate identification of pigmented RPE cells. Subretinal injections of the three-week-old rats examined in this study and immunosuppression treatments were described previously [8]; injections were performed using protocols outlined previously in strict accordance with ethical guidelines of TSRI [32]. In brief, single RPE cells suspended in PBS were injected in a 0.5 μL volume into the subretinal space. Pathologists and support staff at TSRI, UCSD (Department of Pathology), IDEXX RADIL, and Antech Diagnostics performed necropsies, analyzed selected tissues, and performed blood-work using standard protocols.

2.2. iPS Generation and RPE Differentiation

iPSCs were reprogrammed from somatic cells either using OCT4 and small molecules (1F-iPS) [33] or with episomal vectors (EiPS) [34] and iPS-RPE were generated from both lines using directed differentiation as demonstrated in a multimedia protocol [35].

2.3. Cytology

Our established protocols for isolating and culturing RPE, immunocytochemistry, and immunohistochemistry have been described previously [8, 34]. Primary cultures were performed as described previously [8] from eyes from 2-year-1-month-, 2-year-2-month-, and 2-year-5-month-old albino RCS rats injected with iPS-RPE. The phagocytosis assay was performed as described previously [34] and briefly as follows: untreated cells were used to obtain baseline fluorescence. Cells were challenged with FITC labeled outer segments and incubated at 37°C for five hours. Cells were then rinsed with 1X Dulbecco’s PBS and treated with trypsin (TrypLE; Invitrogen) for 5 to 8 minutes to detach cells and release bound outer segments. DMEM/F12 (Invitrogen) containing 2% FBS (Invitrogen) was added and samples were diluted 1 : 1 with FACS staining buffer (BD) containing DRAQ5 (1 : 2500; Cell Signaling) to distinguish cells from debris and outer segments. Samples were analyzed using a FACSCanto flow cytometer (BD) and gated based on DRAQ5 labeling. 5000 events were collected per sample. Data were analyzed using FlowJo software (version 8.8.6; Tree Star, Inc., Ashland, OR).

2.4. Transmission Electron Microscopy

For transmission electron microscopy, eye cups were fixed in 4% paraformaldehyde plus 1.5% glutaraldehyde in 0.1 M sodium cacodylate buffer overnight at 4°C followed by rinsing in 0.1 M Na cacodylate buffer for 1 h. Eyecups were postfixed in 1% osmium tetroxide in 0.1 M sodium cacodylate buffer for 2 h and then dehydrated in graded ethanol solutions. The tissues were incubated overnight in a 1 : 2 mixture of propylene oxide and Epon/Araldite (Sigma-Aldrich) and placed in 100% resin followed by embedding. The blocks were sectioned and used for high-magnification electron microscopy analysis. For immunohistochemistry, tissues were processed using standardized protocols [8]. Anti-Tra-I-85 (Abcam) [20], anti-OTX2 (R&D Systems), and anti-Iba1 (Wako) antibodies were used.

3. Results

A review of the daily monitoring reports from our colony revealed no obvious health or behavioral differences between iPS-RPE treated and untreated animals (SI Table 1 available online at http://dx.doi.org/10.1155/2016/8470263). There were also no significant differences between the weights of the uninjected, PBS injected, or iPS-RPE injected RCS rats (data not shown). Necropsies were performed on a subset of the animals with iPS-RPE implants and blood, eyes, brain, liver, and spleens were removed for more rigorous inspections (). Pathologists noted only aging-related phenomena including moderate splenic hemosiderosis, scattered (and mild) accumulations of hemosiderin- or lipofuscin-laden macrophages in some of the livers, and mammary tissues that appeared granular with pockets of white and occasional pale yellow fluids.

The blood test results also revealed no unusual abnormalities and were largely within normal reference levels (Table 1). White blood cell counts and mean corpuscle hemoglobin concentration levels were very mildly attenuated, while hemocrit levels were very slightly elevated. Slight polychromasia was seen in 4/7 male rats and, in one of those, moderate anisocytosis was evident. In general the erythrocytes were slightly normocytic and borderline hypochromic. All of these changes are more consistent with aging and unlikely to be due to chronic inflammation associated with the allografts.

(a)

SexAgeWBCRBCHGBHCTMCVMCHMCHCRBC Morph.

M1 y 10 m5.38.318.3526319.731Normal
M1 y 10 m5.98.616.8526019.632PC
M1 y 5 m8.77.614.8496419.430PC
M1 y 5 m4.58.816.4536018.731Normal
M1 y 5 m4.58.716.3526018.731PC
M1 y 5 m78.916.7556218.830PC/AN
F1 y 6 m3.77.514.2476318.930Normal
M1 y 6 m5.48.315.6526218.730Normal
F1 y 5 m4.87.815496319.331Normal
F1 y 5 m3.77.113.7466519.330Normal

Ave.5.48.215.8516219.131n/a
Ref. range5.5–115.5–10.510.6–17.233–5047–6615–2331–38n/a
Units103/L106/Lg/dL%fLpgg/dLn/a

(b)

SexAgePlatelet Ct.Platelet Est.NeutrophilsLymphocytesMonocytesEosinophils

M1 y 10 m1101Increased1060 (20%)4028 (76%)106 (2%)106 (2%)
M1 y 10 m377Adequate2537 (43%)3127 (53%)118 (2%)118 (2%)
M1 y 5 m1251Increased5133 (59%)3306 (38%)174 (2%)87 (1%)
M1 y 5 m1133Increased945 (21%)3465 (77%)45 (1%)45 (1%)
M1 y 5 m1176Increased990 (22%)3330 (74%)45 (1%)90 (2%)
M1 y 5 m1110Adequate2450 (35%)4340 (62%)70 (1%)140 (2%)
F1 y 6 m1038Adequate1147 (31%)2405 (65%)74 (2%)74 (2%)
M1 y 6 m1242Adequate1674 (31%)3510 (65%)108 (2%)108 (2%)
F1 y 5 m817Adequate1632 (34%)3072 (64%)48 (1%)48 (1%)
F1 y 5 m667Adequate925 (25%)2664 (72%)37 (1%)74 (2%)

Units103/L/L/L/L/L/L

Ultrastructural examinations reveal that iPS-RPE injected as a suspension of cells can integrate into the subretinal space (Figure 1(a)). Examining single implanted cells at this magnification is useful for identifying subcellular structures including melanosomes (host albino cells have no melanosomes), basal infoldings, and long apical extensions, all characteristic of mature polarized RPE. After as late as 2.5 years after implantation, pigmented areas resembling grafted RPE can still be observed under the retina of enucleated eyes (Figures 1(b)1(e)) compared with control uninjected regions (Figure 1(f)). Aging iPS-RPE grafts retain characteristics and features typical of RPE cells (Figures 2(a) and 2(b)). In addition, immunohistochemistry assays revealed that anti-human Tra-I-85 antibodies decorated the outer surface of the pigmented cells in the subretinal space (Figure 2(d)). These same cells were not immunoreactive for Iba1, a marker of activated microglia, thereby providing additional evidence that the cells are human iPS-RPE.

Conversely, Iba1 positive and Tra-I-85 negative melanin-laden cells were abundant in scattered patterns through the retina, but not in RPE domains. This lack of overlap of Iba1 and Tra-I-85 signals strongly suggests that these cells are host macrophages that ingested displaced human RPE cells (Figures 2(d)2(e)). The survival potential for iPS-RPE in the subretinal space is notable, but since no ERG responses were detectable 18 weeks after injection (data not shown), these data suggest that iPS-RPE can provide only limited rescue in RCS rat retinas.

Additional evidence that these are human RPE, and not host macrophages, is that they could be isolated from old animals, be maintained in culture, and phagocytose photoreceptor outer segments with previously established RPE binding/internalization parameters [36]. RPE primary cultures were generated from the eyes of 2.1-, 2.2-, and 2.5-year-old RCS rats (Figure 3(a)). The already existing challenges of generating pure primary RPE cultures are greatly exacerbated in old albino RCS rats since multiple non-RPE cells types and blood vessels populate the subretinal space [37]. Immunocytochemistry analyses with an antibody that only recognizes human OTX2, a molecular RPE marker, revealed that some of the isolated cells were human RPE (Figure 3(b)). When challenged with isolated porcine outer segments, some of the cells bound and internalized them in a manner consistent with RPE phagocytosis dynamics (Figure 3(c)) [34, 36]. This result strongly suggests that the 2+-year-old iPSC-RPE grafted cells are stable in the subretinal space and maintain phagocytic capacity even during retinal remodeling associated with retinal degeneration [38].

4. Discussion

Using iPSC technology, it is possible to generate large numbers of autologous RPE cells for transplantation that strongly resemble primary human RPE. In our previous study we showed that iPS-RPE provide transient anatomical and functional rescue in RCS rats [8]. In this study we were able to continue monitoring the same animals through the duration of their lives in order to determine the long-term efficacy and safety of RPE cell replacement therapy. By examining the viability and function of the same cells in the same animals both in our 2012 study and in this one, we draw the following conclusions: (a) hiPS-RPE that integrate into the subretinal space can provide transient neurotrophism (up to 18 weeks after injection) for photoreceptors. Nonintegrating cells can be cleared by host macrophages, even in immunocompromised states, without inducing features of chronic inflammation. This data is supported through evidence gathered using histology, optical coherence tomography, and focal ERG in iPS-RPE implanted eyes. (b) Implanted iPS-RPE outlive the photoreceptors, retain phagocytic function, and persist in the subretinal space during the entire course of the animals’ lives. (c) Based on the parameters examined in this study, we report no obvious complications due to exogenous RPE delivery, as long as the cells integrate properly. (d) Abnormalities observed were due to cell reflux and other complications from the subretinal injections (SI Figure 1). These complications are likely to be minimized since the subretinal injections will be performed by skilled vitreoretinal surgeons in much bigger eyes using optimized protocols [13, 39].

Reports indicate that stem cell-derived RPE survive for only 13 weeks and as long as >220 days in the subretinal space [4, 6, 10]. Furthermore, implanted RPE cells can form aggregates and double-layered structures with iPSC-RPE and host RPE [4, 6, 9, 10]. Other groups are now focused on culturing RPE cells either as intact sheets or on synthetic substrates to facilitate delivery of intact monolayers. Evidence suggests that RPE delivered using this method may enhance stability of the grafts, but this approach does not ultimately seem to prolong the photoreceptor rescue effects [25] and involves a more complicated surgery. Of the 31 eyes examined in this study, iPS-RPE were fundoscopically detectable in all of them after delivering the cell in suspension, and histological examinations revealed the presence of integrated and unintegrated (primarily directly around the injection site) cells. Ultimately, the integrated cells exhibited polarity and pigmentation characteristic of intact RPE monolayers and survived for as long as two and a half years. Therefore, both approaches have their own advantages and limitations, and the decision to implant RPE cells in suspension or on scaffolds may require case-by-case decisions based on the integrity of Bruch’s membrane.

5. Conclusion

In summary we see no evidence of abnormal RPE cell migration and no evidence of tumorigenesis or chronic inflammation up to 2 1/2 years after implantation. iPSC-RPE injected as a cell suspension can stably integrate into the retina and, despite the fact that they cannot provide permanent photoreceptor rescue, retain phagocytic function and are observed throughout the lives of the rats without eliciting gross detrimental effects. This study confirms findings from other groups that RPE transplantation does not likely represent a cure [9, 10]. However, based on our previous and current findings, RPE cell transplantation can provide significant therapeutic benefits without inducing off-target deleterious effects.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors wish to acknowledge assistance from Drs. Lea Scheppke and Alan Bird for critically evaluating the paper. They also acknowledge technical assistance from Dr. Malcolm R. Wood at the EM Core Facility, Michele Courtney in the TSRI Pathology Lab, and Dr. Shari Hamilton at IDEXX RADIL. This work was funded by grants from The California Institute of Regenerative Medicine (CIRM TR1-01219) and The Lowy Medical Research Institute to Martin Friedlander and from the National Eye Institute to Martin Friedlander (EY11254) and Jonathan H. Lin (EY020846) and by the National Institutes of Health under Ruth L. Kirschstein National Research Service Award EY021416 to Peter D. Westenskow.

Supplementary Materials

A table (SI Table 1) summarizing the daily health and behavior reports for the rats involved in this study and images showing occasional complications involved with the subretinal injections (SI Figure 1) are included in the supplemental material.

  1. Supplementary Material

References

  1. O. Strauss, “The retinal pigment epithelium in visual function,” Physiological Reviews, vol. 85, no. 3, pp. 845–881, 2005. View at: Publisher Site | Google Scholar
  2. N. Congdon, B. O’Colmain, C. C. Klaver et al., “Causes and prevalence of visual impairment among adults in the United States,” Archives of Ophthalmology, vol. 122, no. 4, pp. 477–485, 2004. View at: Publisher Site | Google Scholar
  3. P. V. Algvere, L. Berglin, P. Gouras, and Y. Sheng, “Transplantation of fetal retinal pigment epithelium in age-related macular degeneration with subfoveal neovascularization,” Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 232, no. 12, pp. 707–716, 1994. View at: Publisher Site | Google Scholar
  4. A.-J. Carr, A. A. Vugler, S. T. Hikita et al., “Protective effects of human iPS-derived retinal pigment epithelium cell transplantation in the retinal dystrophic rat,” PLoS ONE, vol. 4, no. 12, Article ID e8152, 2009. View at: Publisher Site | Google Scholar
  5. C. I. Falkner-Radler, I. Krebs, C. Glittenberg et al., “Human retinal pigment epithelium (RPE) transplantation: outcome after autologous RPE-choroid sheet and RPE cell-suspension in a randomised clinical study,” British Journal of Ophthalmology, vol. 95, no. 3, pp. 370–375, 2011. View at: Publisher Site | Google Scholar
  6. M. Idelson, R. Alper, A. Obolensky et al., “Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells,” Cell Stem Cell, vol. 5, no. 4, pp. 396–408, 2009. View at: Publisher Site | Google Scholar
  7. I. Klimanskaya, J. Hipp, K. A. Rezai, M. West, A. Atala, and R. Lanza, “Derivation and comparative assessment of retinal pigment epithelium from human embryonic stem cells using transcriptomics,” Cloning and Stem Cells, vol. 6, no. 3, pp. 217–245, 2004. View at: Publisher Site | Google Scholar
  8. T. U. Krohne, P. D. Westenskow, T. Kurihara et al., “Generation of retinal pigment epithelial cells from small molecules and OCT4 reprogrammed human induced pluripotent stem cells,” Stem Cells Translational Medicine, vol. 1, no. 2, pp. 96–109, 2012. View at: Publisher Site | Google Scholar
  9. Y. Li, Y.-T. Tsai, C.-W. Hsu et al., “Long-term safety and efficacy of human-induced pluripotent stem cell (iPS) grafts in a preclinical model of retinitis pigmentosa,” Molecular Medicine, vol. 18, no. 9, pp. 1312–1319, 2012. View at: Publisher Site | Google Scholar
  10. B. Lu, C. Malcuit, S. Wang et al., “Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration,” STEM CELLS, vol. 27, no. 9, pp. 2126–2135, 2009. View at: Publisher Site | Google Scholar
  11. R. D. Lund, S. Wang, I. Klimanskaya et al., “Human embryonic stem cell-derived cells rescue visual function in dystrophic RCS rats,” Cloning and Stem Cells, vol. 8, no. 3, pp. 189–199, 2006. View at: Publisher Site | Google Scholar
  12. G. A. Peyman, K. J. Blinder, C. L. Paris, W. Alturki, N. C. Nelson Jr., and U. Desai, “A technique for retinal pigment epithelium transplantation for age-related macular degeneration secondary to extensive subfoveal scarring,” Ophthalmic Surgery, vol. 22, no. 2, pp. 102–108, 1991. View at: Google Scholar
  13. S. D. Schwartz, J.-P. Hubschman, G. Heilwell et al., “Embryonic stem cell trials for macular degeneration: a preliminary report,” The Lancet, vol. 379, no. 9817, pp. 713–720, 2012. View at: Publisher Site | Google Scholar
  14. A. Vugler, A.-J. Carr, J. Lawrence et al., “Elucidating the phenomenon of HESC-derived RPE: anatomy of cell genesis, expansion and retinal transplantation,” Experimental Neurology, vol. 214, no. 2, pp. 347–361, 2008. View at: Publisher Site | Google Scholar
  15. A.-J. F. Carr, M. J. K. Smart, C. M. Ramsden, M. B. Powner, L. da Cruz, and P. J. Coffey, “Development of human embryonic stem cell therapies for age-related macular degeneration,” Trends in Neurosciences, vol. 36, no. 7, pp. 385–395, 2013. View at: Publisher Site | Google Scholar
  16. P. V. Algvere, P. Gouras, and E. Dafgard Kopp, “Long-term outcome of RPE allografts in non-immunosuppressed patients with AMD,” European Journal of Ophthalmology, vol. 9, no. 3, pp. 217–230, 1999. View at: Google Scholar
  17. X. Zhang and D. Bok, “Transplantation of retinal pigment epithelial cells and immune response in the subretinal space,” Investigative Ophthalmology and Visual Science, vol. 39, no. 6, pp. 1021–1027, 1998. View at: Google Scholar
  18. T. Zhao, Z. N. Zhang, P. D. Westenskow et al., “Humanized mice reveal differential immunogenicity of cells derived from autologous induced pluripotent stem cells,” Cell Stem Cell, vol. 17, no. 3, pp. 353–359, 2015. View at: Publisher Site | Google Scholar
  19. D. E. Buchholz, S. T. Hikita, T. J. Rowland et al., “Derivation of functional retinal pigmented epithelium from induced pluripotent stem cells,” Stem Cells, vol. 27, no. 10, pp. 2427–2434, 2009. View at: Publisher Site | Google Scholar
  20. A.-J. Carr, A. Vugler, J. Lawrence et al., “Molecular characterization and functional analysis of phagocytosis by human embryonic stem cell-derived RPE cells using a novel human retinal assay,” Molecular vision, vol. 15, pp. 283–295, 2009. View at: Google Scholar
  21. Y. Hirami, F. Osakada, K. Takahashi et al., “Generation of retinal cells from mouse and human induced pluripotent stem cells,” Neuroscience Letters, vol. 458, no. 3, pp. 126–131, 2009. View at: Publisher Site | Google Scholar
  22. M. Kokkinaki, N. Sahibzada, and N. Golestaneh, “Human induced pluripotent stem-derived retinal pigment epithelium (RPE) cells exhibit ion transport, membrane potential, polarized vascular endothelial growth factor secretion, and gene expression pattern similar to native RPE,” Stem Cells, vol. 29, no. 5, pp. 825–835, 2011. View at: Publisher Site | Google Scholar
  23. J. S. Meyer, R. L. Shearer, E. E. Capowski et al., “Modeling early retinal development with human embryonic and induced pluripotent stem cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 39, pp. 16698–16703, 2009. View at: Publisher Site | Google Scholar
  24. F. Osakada, Z.-B. Jin, Y. Hirami et al., “In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction,” Journal of Cell Science, vol. 122, part 17, pp. 3169–3179, 2009. View at: Publisher Site | Google Scholar
  25. B. Diniz, P. Thomas, B. Thomas et al., “Subretinal implantation of retinal pigment epithelial cells derived from human embryonic stem cells: improved survival when implanted as a monolayer,” Investigative Ophthalmology & Visual Science, vol. 54, no. 7, pp. 5087–5096, 2013. View at: Publisher Site | Google Scholar
  26. H. Kamao, M. Mandai, S. Okamoto et al., “Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application,” Stem Cell Reports, vol. 2, no. 2, pp. 205–218, 2014. View at: Publisher Site | Google Scholar
  27. S. D. Schwartz, C. D. Regillo, B. L. Lam et al., “Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies,” The Lancet, vol. 385, no. 9967, pp. 509–516, 2015. View at: Publisher Site | Google Scholar
  28. W. Song, K. Park, H. Kim et al., “Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in asian patients,” Stem Cell Reports, vol. 4, no. 5, pp. 860–872, 2015. View at: Publisher Site | Google Scholar
  29. T. M. Nork, C. J. Murphy, C. B. Y. Kim et al., “Functional and anatomic consequences of subretinal dosing in the cynomolgus macaque,” Archives of Ophthalmology, vol. 130, no. 1, pp. 65–75, 2012. View at: Publisher Site | Google Scholar
  30. W. H. Ross and F. A. Stockl, “Visual recovery after retinal detachment,” Current Opinion in Ophthalmology, vol. 11, no. 3, pp. 191–194, 2000. View at: Publisher Site | Google Scholar
  31. P. M. D’Cruz, D. Yasumura, J. Weir et al., “Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat,” Human Molecular Genetics, vol. 9, no. 4, pp. 645–651, 2000. View at: Publisher Site | Google Scholar
  32. P. D. Westenskow, T. Kurihara, S. Bravo et al., “Performing subretinal injections in rodents to deliver retinal pigment epithelium cells in suspension,” Journal of Visualized Experiments, no. 95, Article ID e52247, 2015. View at: Publisher Site | Google Scholar
  33. S. Zhu, W. Li, H. Zhou et al., “Reprogramming of human primary somatic cells by OCT4 and chemical compounds,” Cell Stem Cell, vol. 7, no. 6, pp. 651–655, 2010. View at: Publisher Site | Google Scholar
  34. P. D. Westenskow, S. K. Moreno, T. U. Krohne et al., “Using flow cytometry to compare the dynamics of photoreceptor outer segment phagocytosis in iPS-derived RPE cells,” Investigative Ophthalmology & Visual Science, vol. 53, no. 10, pp. 6282–6290, 2012. View at: Publisher Site | Google Scholar
  35. P. D. Westenskow, Z. Sedillo, A. Barnett, and M. Friedlander, “Efficient derivation of retinal pigment epithelium cells from stem cells,” Journal of Visualized Experiments, no. 97, Article ID e52214, 2015. View at: Publisher Site | Google Scholar
  36. S. C. Finnemann, V. L. Bonilha, A. D. Marmorstein, and E. Rodriguez-Boulan, “Phagocytosis of rod outer segments by retinal pigment epithelial cells requires αvβ5 integrin for binding but not for internalization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 24, pp. 12932–12937, 1997. View at: Publisher Site | Google Scholar
  37. M. L. Weber, M. A. Mancini, and R. N. Frank, “Retinovitreal neovascularization in the royal college of surgeons rat,” Current Eye Research, vol. 8, no. 1, pp. 61–74, 1989. View at: Publisher Site | Google Scholar
  38. B. W. Jones and R. E. Marc, “Retinal remodeling during retinal degeneration,” Experimental Eye Research, vol. 81, no. 2, pp. 123–137, 2005. View at: Publisher Site | Google Scholar
  39. S. Binder, U. Stolba, I. Krebs et al., “Transplantation of autologous retinal pigment epithelium in eyes with foveal neovascularization resulting from age-related macular degeneration: a pilot study,” American Journal of Ophthalmology, vol. 133, no. 2, pp. 215–225, 2002. View at: Publisher Site | Google Scholar

Copyright © 2016 Peter D. Westenskow et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

1237 Views | 597 Downloads | 10 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.